Healthcare Industry News: GSK
News Release - July 11, 2011
Ascletis Names Allan Baxter, PhD, Former GlaxoSmithKline Global Head of Medicines Development, as Chief Strategy Officer
RESEARCH TRIANGLE PARK, N.C. & HANGZHOU, China--(Healthcare Sales & Marketing Network)-- Ascletis, Inc., a U.S.-China pharmaceutical company developing important medicines for cancer and infectious diseases, today announced the appointment of Allan Baxter, Ph.D. as Chief Strategy Officer. Dr. Baxter, who has been an advisor to Ascletis since its founding, joins Ascletis following a 30 year career at GlaxoSmithKline (GSK), where he ultimately served as Senior Vice President and Global Head of Medicines Development with accountability for GSK’s late-stage drug development pipeline.“Ascletis represents an exciting opportunity to develop medicines both for the specific needs of the rapidly growing China pharmaceutical markets and for global market opportunities,” said Dr. Baxter. “I look forward to working with the Ascletis team to build the company’s discovery and development pipeline in the areas of cancer and infectious diseases.”
During his long career at GSK, Dr. Baxter had worldwide responsibility for GSK’s late-stage portfolio of investigational medicines from Phase 2 through regulatory approval and lifecycle management. He also created and led six Centres of Excellence for Drug Discovery within GSK. Dr. Baxter received his Ph.D. in biochemistry and honorary D. Sc. from Glasgow University. He is Chairman of Stevenage Bioscience Catalyst, an independent U.K.-based life sciences facility for early stage biotechnology companies, and Chair of the Wellcome Trust’s Seeding Drug Discovery Funding Committee. Dr. Baxter is also a non-executive director of Human Genome Sciences and Vernalis plc.
About Ascletis, Inc.
Ascletis is a joint venture between U.S. and Chinese entrepreneurs aimed at building a global specialty therapeutics business dedicated to discovering and developing important new treatments for cancer and infectious diseases. Ascletis leverages U.S./European innovation and pharmaceutical/biotech strategic experience and China’s capital efficiency with a goal of establishing in the near term a sustainable business and accelerated revenues through the in-licensing, late-stage clinical development, and commercialization of new medicines for the growing Chinese pharmaceutical marketplace. At the same time, the company is building long-term value through the discovery, demonstration of clinical proof-of-concept, and global partnering of novel therapeutics for life-threatening diseases. For more information, please visit http://www.ascletis.com.
Source: Ascletis
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
